INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 48m ago
HOUSE PTR8m ago
SEC 13F8m ago
ROBINHOOD CHAIN8m ago
Public company

SPRYARS Pharmaceuticals, Inc.

CIK 0001671858

EDGAR filingsOpen in network
Disclosed transactions12
Buys / sells0 / 3
Max Insider Score42
Connections7with evidence

SPRY · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
SL
Slebir John LChief Legal Officer
SPRYARS Pharmaceuticals, Inc.
Grant or award
A—
1.20M sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Slebir John LChief Legal Officer · Nov 4, 2026
  • ← Insider ofevidence
    Smith Margaret EkinsChief Commercial Officer · Sep 2, 2026
  • ← Insider ofevidence
    Casale DonnPresident · Jul 2, 2026
9
CD
Casale DonnDirector, President and CEO
SPRYARS Pharmaceuticals, Inc.
Grant or award
A
—
1.04M sh
Oct 1, 2026
Oct 5, 2026
traded Oct 1, 2026
+4d
SEC FORM 4

Evidence

9
SE
Smith Margaret EkinsChief Commercial Officer
SPRYARS Pharmaceuticals, Inc.
Grant or award
A—
1.00M sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

9
CD
Casale DonnPresident
SPRYARS Pharmaceuticals, Inc.
Grant or award
A—
898.5K sh
Jul 1, 2026Jul 2, 2026
traded Jul 1, 2026
+1dSEC FORM 4

Evidence

9
KM
Kelly MichaelDirector
SPRYARS Pharmaceuticals, Inc.
Grant or award
A—
30.0K sh
Jun 24, 2026Jun 26, 2026
traded Jun 24, 2026
+2dSEC FORM 4

Evidence

11
KE
Karas EricChief Commercial Officer
SPRYARS Pharmaceuticals, Inc.
Option exercise · 10b5-1 plan
M$38K
25.0K sh
Jun 12, 2026Jun 12, 2026
traded Jun 12, 2026
+0dSEC FORM 4

Evidence

23
KE
Karas EricChief Commercial Officer
SPRYARS Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$250K
25.0K sh
Jun 12, 2026Jun 12, 2026
traded Jun 12, 2026
+0dSEC FORM 4

Evidence

3
KE
Karas EricChief Commercial Officer
SPRYARS Pharmaceuticals, Inc.
Option exercise · 10b5-1 plan
M—
25.0K sh
Jun 12, 2026Jun 12, 2026
traded Jun 12, 2026
+0dSEC FORM 4

Evidence

17
CJ
Chakma JustinChief Business Officer
SPRYARS Pharmaceuticals, Inc.
Option exercise
M$25K
30.0K sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC FORM 4

Evidence

21
CJ
Chakma JustinChief Business Officer
SPRYARS Pharmaceuticals, Inc.
Option exercise
M—
30.0K sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC FORM 4

Evidence

42
CJ
Chakma JustinChief Business Officer
SPRYARS Pharmaceuticals, Inc.
Open-market sale
SELL$1.21M
136.4K sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC FORM 4

Evidence

31
CJ
Chakma JustinChief Business Officer
SPRYARS Pharmaceuticals, Inc.
Open-market sale
SELL$267K
30.0K sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Kelly MichaelDirector · Jun 26, 2026
  • ← Insider ofevidence
    Karas EricChief Commercial Officer · Jun 12, 2026
  • ← Insider ofevidence
    Chakma JustinChief Business Officer · Nov 14, 2025